Other equities analysts also recently issued research reports about the company. HC Wainwright downgraded Hydrogenics from a buy rating to a neutral rating in a research note on Friday, June 28th. Zacks Investment Research downgraded GENEL ENERGY PL/ADR from a buy rating to a hold rating in a research note on Tuesday, May 7th.
Shares of NASDAQ EVOK opened at $0.88 on Tuesday. Evoke Pharma has a twelve month low of $0.50 and a twelve month high of $3.40. The business has a 50 day simple moving average of $0.66. The stock has a market cap of $20.47 million, a P/E ratio of -1.91 and a beta of 1.62.
Institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in Evoke Pharma in the first quarter valued at approximately $118,000. BlackRock Inc. lifted its stake in Evoke Pharma by 5.5% in the fourth quarter. BlackRock Inc. now owns 83,583 shares of the specialty pharmaceutical company’s stock valued at $207,000 after purchasing an additional 4,392 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in Evoke Pharma in the first quarter valued at approximately $139,000. Institutional investors and hedge funds own 7.40% of the company’s stock.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
See Also: Exchange-Traded Funds (ETFs)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.